(Q39839514)

15 September 2017

title

Quality-of-life tradeoffs for hepatitis C treatment: do patients and providers agree? (English)

1 reference

15 September 2017

1 reference

1

Bruce R Schackman

1 reference

15 September 2017

4

Alvin I Mushlin

1 reference

15 September 2017

Paul A Teixeira

2

1 reference

15 September 2017

Gil Weitzman

series ordinal

3

1 reference

15 September 2017

Ira M Jacobson

series ordinal

5

1 reference

15 September 2017

language of work or name

1 reference

18 March 2008

1 reference

15 September 2017

published in

Medical Decision Making

1 reference

15 September 2017

volume

28

1 reference

15 September 2017

issue

2

1 reference

15 September 2017

page(s)

233-242

1 reference

Treating viral hepatitis C: efficacy, side effects, and complications

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Reasons for non-treatment of hepatitis C in veterans in care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Surprisingly small effect of antiviral treatment in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Barriers to the treatment of hepatitis C. Patient, provider, and system factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Assessment of utilities and health-related quality of life in patients with chronic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Health values of patients with chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Hepatitis C, interferon alfa, and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Depression, anemia and health-related quality of life in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Treatment of hepatitis C in HIV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Hepatitis C in the HIV-Infected Person

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

"They treated me like a leper". Stigmatization and the quality of life of patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Hepatitis C virus-infected patients report communication problems with physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Social stigmatization and hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Physicians' preference values for hepatitis C health states and antiviral therapy: a survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Effects on preferences of violations of procedural invariance

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Patient preferences for adjuvant interferon alfa-2b treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Assessing values for health: numeracy matters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Whose utilities for decision analysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Differences in health values among patients, family members, and providers for outcomes in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Race, gender, and partnership in the patient-physician relationship

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Primary care physicians who treat blacks and whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: outcomes from a population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Impact of chronic viral hepatitis on health-related quality of life in HIV: results from a nationally representative sample.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Health values of patients coinfected with HIV/hepatitis C: are two viruses worse than one?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Offers of hepatitis C care do not lead to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

The impact of diagnosis of hepatitis C virus on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Chronic hepatitis C virus infection: does it really impact health-related quality of life? A study in rural Egypt

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Empirically calibrated model of hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Update on chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Treating hepatitis C virus infection in active substance users

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Integrating treatment for hepatitis C virus infection into an HIV clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

The role of hepatitis C support groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

Health-State Utilities and Quality of Life in Hepatitis C Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0272989X07311753

21 January 2018

Identifiers

DOI

10.1177/0272989X07311753

1 reference

15 September 2017

1 reference